Haemonetics Corporation $HAE Shares Acquired by PDT Partners LLC

Key Points

• PDT Partners LLC significantly increased its holdings in Haemonetics Corporation by 441.9%, owning 55,101 shares worth approximately $3.5 million as of the end of the last quarter.
• Haemonetics reported $1.10 EPS for the last quarter, exceeding analysts' estimates by $0.09, although its revenue of $321.39 million was down 4.4% year-over-year.
• Analysts have mixed ratings on Haemonetics, with a consensus rating of "Moderate Buy" and a target price around $85.18, amid varied assessments from several financial firms.

PDT Partners LLC boosted its holdings in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 441.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,101 shares of the medical instruments supplier's stock after buying an additional 44,933 shares during the quarter. PDT Partners LLC owned approximately 0.11% of Haemonetics worth $3,502,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of HAE. Quarry LP increased its holdings in Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after buying an additional 192 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new position in Haemonetics during the first quarter valued at approximately $65,000. KBC Group NV increased its holdings in Haemonetics by 19.9% during the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after buying an additional 401 shares during the period. AlphaQuest LLC increased its holdings in Haemonetics by 71.5% during the first quarter. AlphaQuest LLC now owns 3,140 shares of the medical instruments supplier's stock valued at $200,000 after buying an additional 1,309 shares during the period. Finally, Vise Technologies Inc. increased its holdings in Haemonetics by 8.7% during the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after buying an additional 225 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HAE has been the topic of several analyst reports. Robert W. Baird initiated coverage on shares of Haemonetics in a report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price target on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price target on shares of Haemonetics in a report on Tuesday, May 20th. Raymond James Financial lowered shares of Haemonetics from a "strong-buy" rating to an "outperform" rating and cut their price target for the stock from $105.00 to $78.00 in a report on Monday, August 11th. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $62.00 price target (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and an average price target of $85.18.

Haemonetics Stock Performance

NYSE HAE traded up $0.26 on Friday, reaching $54.34. 627,638 shares of the company's stock traded hands, compared to its average volume of 1,077,717. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of 16.62, a P/E/G ratio of 1.00 and a beta of 0.39. The stock has a 50 day moving average price of $66.04 and a 200-day moving average price of $65.74. Haemonetics Corporation has a fifty-two week low of $50.68 and a fifty-two week high of $94.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. The company had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm's quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities research analysts predict that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.